CRVO — CervoMed Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1053691 ·
Last close
$3.57
Market Cap
$33.05M
52W High
$7.81
52W Low
$2.13
ADV30
11,321,810
Next earnings
2026-08-13
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -8,110,524 -7,964,158 15,112,918 7,941,751 4,497,203
Dec 2025 0 -8,331,519 -8,087,290 22,879,018 8,235,469 4,656,117
Sep 2025 0 -8,044,199 -7,726,639 30,610,778 9,437,400 4,599,314
Jun 2025 0 -6,616,275 -6,258,404 38,081,399 8,320,713 4,641,620

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-27,573,942
Investing CF
$20,411,492
Financing CF
$4,602,487
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.10
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-105,662,009
Inventory
Receivables
$0
ST Investments
$4,982,230
EBIT TTM
$-31,102,517
Pretax Income TTM
$-30,036,491
Interest Exp TTM
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,089,019
EBITDA
Free Cash Flow
$-16,304,171
Enterprise Value
$21,703,628
Total Cash
$12,923,981
Total Debt
$0
Shares Out
9,258,719
Trailing EPS
$-3.28
Book Value
$1.15
ROE
-132.8%
ROA
-72.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -28,294,877 -26,966,367 22,879,018 4,656,117 -23,449,963
Dec 2024 0 -18,227,131 -16,290,695 43,081,610 3,879,282 -16,530,827
Dec 2023 0 -7,812,895 -2,171,873 9,972,521 2,595,747 -7,449,847
Dec 2022 0 -3,475,534 -5,803,047 4,157,706 37,442,765 -2,572,759

TTM Snapshot

Revenues TTM
$12,839,780
NetIncome TTM
$-6,223,165
OpCashFlow TTM
$0
Assets (Latest)
$17,484,384
Forward EPS
$-2.32

Peers — same industry

TickerNameMarket CapLastDaily %
SER Serina Therapeutics, Inc. $32.09M $2.14
PYRGF PyroGenesis Canada Inc. $34.27M $0.15
BCTX BriaCell Therapeutics Corp. $34.28M $3.94
NSRX Nasus Pharma Ltd $34.31M $2.93
LITS Lite Strategy, Inc. $34.37M $1.01

News headlines (Yahoo Finance, 1h cache)

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
2026-07-09 11:30 · Yahoo
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
2026-07-06 11:30 · Yahoo
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
2026-06-22 20:05 · Yahoo
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally
2026-06-18 17:55 · Yahoo
Top Midday Gainers
2026-06-18 17:32 · Yahoo
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
2026-06-18 16:35 · Yahoo
CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)
2026-06-18 14:08 · Yahoo
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
2026-06-18 11:00 · Yahoo
CervoMed Insiders Lose Out As Stock Sinks To US$2.45
2026-06-14 12:14 · Yahoo
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-12 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.